ArticleJournal of orthopaedic case reports2025
First Documented Hip Replacement in a Palestinian Patient with Ochronotic Alkaptonuria Arthropathy: A Case Report.
Article in Journal of orthopaedic case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Alkaptonuria (AKU) is a genetic disease caused by a deficiency in the homogentisate 1,2-dioxygenase enzyme. This deficiency leads to elevated levels of homogentisic acid and its oxidized form, benzoquinone acetic acid. Together, these substances lead to the bluish-black coloring of the bone and cartilage, along with calcification, inflammation, degeneration, and ultimately osteoporosis. The accumulation of pigments in the spine and major joints can result in ochronotic degenerative arthropathy. Case Report: In this study, we present the case of a 65-year-old Palestinian man who exhibited musculoskeletal manifestations of AKU for 15 years. He was successfully treated with hip replacement, and we conducted a literature analysis to provide a comprehensive summary of the etiology, clinical characteristics, and potential treatments. Conclusion: AKU affects the spine and large joints. At present, there is no cure for this condition. A diet low in Vitamin C, antioxidants, tyrosine, and phenylalanine may delay the progression of AKU, but the long-term consequences are still unknown. Joint replacement may be recommended to relieve joint pain and improve mobility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.